Literature DB >> 15507659

EBNA2 is required for protection of latently Epstein-Barr virus-infected B cells against specific apoptotic stimuli.

Jae Myun Lee1, Kyoung-Ho Lee, Christopher J Farrell, Paul D Ling, Bettina Kempkes, Jeon Han Park, S Diane Hayward.   

Abstract

In addition to functioning as a transcriptional transactivator, Epstein-Barr virus EBNA2 interacts with Nur77 to protect against Nur77-mediated apoptosis. Estrogen-regulated EBNA2 in EREB2-5 cells was replaced by either EBNA2 or EBNA2 with a deletion of conserved region 4 (EBNA2DeltaCR4). Both EBNA2-converted and EBNA2DeltaCR4-converted EREB2-5 cells grew in the absence of estrogen and expressed LMP1. Treatment with tumor necrosis factor alpha did not induce apoptosis of EBNA2- or EBNA2DeltaCR4-expressing cells, but EBNA2DeltaCR4 cells were susceptible to etoposide and 5-fluorouracil, Nur77-mediated inducers of apoptosis. Thus, EBNA2 protects B cells against specific apoptotic agents against which LMP1 is not effective.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15507659      PMCID: PMC525073          DOI: 10.1128/JVI.78.22.12694-12697.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Epstein-Barr virus nuclear protein 2 interacts with p300, CBP, and PCAF histone acetyltransferases in activation of the LMP1 promoter.

Authors:  L Wang; S R Grossman; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  Truncated mammalian Notch1 activates CBF1/RBPJk-repressed genes by a mechanism resembling that of Epstein-Barr virus EBNA2.

Authors:  J J Hsieh; T Henkel; P Salmon; E Robey; M G Peterson; S D Hayward
Journal:  Mol Cell Biol       Date:  1996-03       Impact factor: 4.272

3.  Epstein-Barr virus nuclear antigen 2-estrogen receptor fusion proteins transactivate viral and cellular genes and interact with RBP-J kappa in a conditional fashion.

Authors:  B Kempkes; M Pawlita; U Zimber-Strobl; G Eissner; G Laux; G W Bornkamm
Journal:  Virology       Date:  1995-12-20       Impact factor: 3.616

4.  The Epstein-Barr virus nuclear protein 2 acidic domain forms a complex with a novel cellular coactivator that can interact with TFIIE.

Authors:  X Tong; R Drapkin; R Yalamanchili; G Mosialos; E Kieff
Journal:  Mol Cell Biol       Date:  1995-09       Impact factor: 4.272

5.  Genetic and biochemical evidence that EBNA 2 interaction with a 63-kDa cellular GTG-binding protein is essential for B lymphocyte growth transformation by EBV.

Authors:  R Yalamanchili; X Tong; S Grossman; E Johannsen; G Mosialos; E Kieff
Journal:  Virology       Date:  1994-11-01       Impact factor: 3.616

6.  The Epstein-Barr virus nuclear protein 2 acidic domain can interact with TFIIB, TAF40, and RPA70 but not with TATA-binding protein.

Authors:  X Tong; F Wang; C J Thut; E Kieff
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

7.  The 62- and 80-kDa subunits of transcription factor IIH mediate the interaction with Epstein-Barr virus nuclear protein 2.

Authors:  X Tong; R Drapkin; D Reinberg; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

8.  Masking of the CBF1/RBPJ kappa transcriptional repression domain by Epstein-Barr virus EBNA2.

Authors:  J J Hsieh; S D Hayward
Journal:  Science       Date:  1995-04-28       Impact factor: 47.728

9.  EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus.

Authors:  A J Sinclair; I Palmero; G Peters; P J Farrell
Journal:  EMBO J       Date:  1994-07-15       Impact factor: 11.598

10.  B-cell proliferation and induction of early G1-regulating proteins by Epstein-Barr virus mutants conditional for EBNA2.

Authors:  B Kempkes; D Spitkovsky; P Jansen-Dürr; J W Ellwart; E Kremmer; H J Delecluse; C Rottenberger; G W Bornkamm; W Hammerschmidt
Journal:  EMBO J       Date:  1995-01-03       Impact factor: 11.598

View more
  19 in total

1.  Epstein-Barr virus and virus human protein interaction maps.

Authors:  Michael A Calderwood; Kavitha Venkatesan; Li Xing; Michael R Chase; Alexei Vazquez; Amy M Holthaus; Alexandra E Ewence; Ning Li; Tomoko Hirozane-Kishikawa; David E Hill; Marc Vidal; Elliott Kieff; Eric Johannsen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-19       Impact factor: 11.205

2.  Epstein-Barr virus nuclear antigen 2 trans-activates the cellular antiapoptotic bfl-1 gene by a CBF1/RBPJ kappa-dependent pathway.

Authors:  Pamela M Pegman; Sinéad M Smith; Brendan N D'Souza; Sinéad T Loughran; Sabine Maier; Bettina Kempkes; Paul A Cahill; Matthew J Simmons; Céline Gélinas; Dermot Walls
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

3.  Epstein-Barr virus encoded EBNA-3 binds to vitamin D receptor and blocks activation of its target genes.

Authors:  Surya Pavan Yenamandra; Ulf Hellman; Bettina Kempkes; Suhas Deoram Darekar; Sabine Petermann; Tom Sculley; George Klein; Elena Kashuba
Journal:  Cell Mol Life Sci       Date:  2010-07-01       Impact factor: 9.261

Review 4.  Targeting NR4A1 (TR3) in cancer cells and tumors.

Authors:  Syng-Ook Lee; Xi Li; Shaheen Khan; Stephen Safe
Journal:  Expert Opin Ther Targets       Date:  2011-01-05       Impact factor: 6.902

5.  Epstein-Barr virus genetic variants are associated with multiple sclerosis.

Authors:  Rosella Mechelli; Caterina Manzari; Claudia Policano; Anita Annese; Ernesto Picardi; Renato Umeton; Arianna Fornasiero; Anna Maria D'Erchia; Maria Chiara Buscarinu; Cristina Agliardi; Viviana Annibali; Barbara Serafini; Barbara Rosicarelli; Silvia Romano; Daniela F Angelini; Vito A G Ricigliano; Fabio Buttari; Luca Battistini; Diego Centonze; Franca R Guerini; Sandra D'Alfonso; Graziano Pesole; Marco Salvetti; Giovanni Ristori
Journal:  Neurology       Date:  2015-03-04       Impact factor: 9.910

6.  U20 is responsible for human herpesvirus 6B inhibition of tumor necrosis factor receptor-dependent signaling and apoptosis.

Authors:  Emil Kofod-Olsen; Katrine Ross-Hansen; Mariane Høgsbjerg Schleimann; Dea Kejlberg Jensen; Janni Michelle Lund Møller; Bettina Bundgaard; Jacob Giehm Mikkelsen; Per Höllsberg
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

7.  Epstein-barr virus-induced resistance to drugs that activate the mitotic spindle assembly checkpoint in Burkitt's lymphoma cells.

Authors:  Maria Leao; Emma Anderton; Mark Wade; Kiran Meekings; Martin J Allday
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

8.  Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells.

Authors:  Gemma L Kelly; Anne E Milner; Gouri S Baldwin; Andrew I Bell; Alan B Rickinson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-25       Impact factor: 11.205

9.  Repression of the proapoptotic cellular BIK/NBK gene by Epstein-Barr virus antagonizes transforming growth factor β1-induced B-cell apoptosis.

Authors:  Eva M Campion; Roya Hakimjavadi; Sinéad T Loughran; Susan Phelan; Sinéad M Smith; Brendan N D'Souza; Rosemary J Tierney; Andrew I Bell; Paul A Cahill; Dermot Walls
Journal:  J Virol       Date:  2014-02-19       Impact factor: 5.103

10.  Truncated form of the Epstein-Barr virus protein EBNA-LP protects against caspase-dependent apoptosis by inhibiting protein phosphatase 2A.

Authors:  Julie Garibal; Emilie Hollville; Andrew I Bell; Gemma L Kelly; Benjamin Renouf; Yasushi Kawaguchi; Alan B Rickinson; Joëlle Wiels
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.